PB2130: MAGNETISMM-6: A PHASE 3 STUDY OF ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE VS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

• Sebastian Grosicki,
• Su-Peng Yeh,
• Shang-Yi Huang,
• Ja Min Byun,
• Christine Dirienzo,
• Andrea Viqueira

Affiliations

Sebastian Grosicki

1 Medical University of Silesia, Department of Hematology and Cancer Prevention

Su-Peng Yeh

2 China Medical University Hospital, Taichung, Taiwan

Shang-Yi Huang

3 Taiwan University Hospital, Taipei, Taiwan

Ja Min Byun

4 Seoul National University Hospital, Seoul, Korea, Rep. of South

Christine Dirienzo

5 Pfizer, Inc., New York, United States

Andrea Viqueira

6 Pfizer SLU, Madrid, Spain